Matches in DBpedia 2014 for { ?s ?p Brexpiprazole (/brɛksˈpɪprəzoʊl/ breks-PIP-rə-zohl; also called OPC-34712) is a novel D2 dopamine partial agonist investigational product currently in clinical trials for the treatment of depression, schizophrenia, and attention deficit hyperactivity disorder (ADHD). It has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).The drug is being developed by Otsuka, and is considered to be a successor of its top-selling antipsychotic agent aripiprazole (brand names: Abilify, Aripiprex). Otsuka's US patent on aripiprazole expires on October 20, 2014;however, due to a pediatric extension, a generic will not become available until at least April 20, 2015.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Brexpiprazole abstract "Brexpiprazole (/brɛksˈpɪprəzoʊl/ breks-PIP-rə-zohl; also called OPC-34712) is a novel D2 dopamine partial agonist investigational product currently in clinical trials for the treatment of depression, schizophrenia, and attention deficit hyperactivity disorder (ADHD). It has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).The drug is being developed by Otsuka, and is considered to be a successor of its top-selling antipsychotic agent aripiprazole (brand names: Abilify, Aripiprex). Otsuka's US patent on aripiprazole expires on October 20, 2014;however, due to a pediatric extension, a generic will not become available until at least April 20, 2015.".